Fundação Belmiro de Azevedo, Portugal Report issue

Academic/Hospital

Organization Overview

First Clinical Trial
2020
NCT04419766
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Fundação Belmiro de Azevedo, Portugal

Active Ingredients

Drugs in Other Trials (1)

3-[n-butyl-n-acetyl]-aminopropionic acid ethyl ester (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1